On the phase structure and thermodynamics of QCD

We discuss the phase structure and thermodynamics of QCD by means of dynamical chiral effective models. Quark and meson fluctuations are included via the functional renormalization group. We study the influence of confinement in addition to the impact of fluctuations by comparing the results of the chiral models to their Polyakov-loop extended versions. Furthermore, we discuss the mass sensitivity of the phase structure and thermodynamics and find interesting modifications close to the chiral limit.Comment: 13 pages, 11 figures; Appendix added; published versio

Exploring the Phase Structure and Thermodynamics of QCD

We put forward a Polyakov-loop extended quark meson model, where matter as well as glue fluctuations are taken into account, cf. [1]. The latter are included via a Polyakov-loop potential. Usually such a glue potential is based on Yang-Mills lattice data only. We show that a parametrisation of unquenching effects as proposed in [2], together with the inclusion of fluctuations via the functional renormalisation group [3,4], accounts for the relevant dynamics. This is demonstrated by a comparison of order parameters and thermodynamic observables to recent lattice results at vanishing chemical potential, where we find very good agreement.Comment: 11 pages, 2 figures, contribution to "QCD-TNT-III: From quarks and gluons to hadronic matter: A bridge too far?", ECT*, Trento (Italy), September 2-6, 201

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016) : part two

Background The immunological escape of tumors represents one of the main ob- stacles to the treatment of malignancies. The blockade of PD-1 or CTLA-4 receptors represented a milestone in the history of immunotherapy. However, immune checkpoint inhibitors seem to be effective in specific cohorts of patients. It has been proposed that their efficacy relies on the presence of an immunological response. Thus, we hypothesized that disruption of the PD-L1/PD-1 axis would synergize with our oncolytic vaccine platform PeptiCRAd. Methods We used murine B16OVA in vivo tumor models and flow cytometry analysis to investigate the immunological background. Results First, we found that high-burden B16OVA tumors were refractory to combination immunotherapy. However, with a more aggressive schedule, tumors with a lower burden were more susceptible to the combination of PeptiCRAd and PD-L1 blockade. The therapy signifi- cantly increased the median survival of mice (Fig. 7). Interestingly, the reduced growth of contralaterally injected B16F10 cells sug- gested the presence of a long lasting immunological memory also against non-targeted antigens. Concerning the functional state of tumor infiltrating lymphocytes (TILs), we found that all the immune therapies would enhance the percentage of activated (PD-1pos TIM- 3neg) T lymphocytes and reduce the amount of exhausted (PD-1pos TIM-3pos) cells compared to placebo. As expected, we found that PeptiCRAd monotherapy could increase the number of antigen spe- cific CD8+ T cells compared to other treatments. However, only the combination with PD-L1 blockade could significantly increase the ra- tio between activated and exhausted pentamer positive cells (p= 0.0058), suggesting that by disrupting the PD-1/PD-L1 axis we could decrease the amount of dysfunctional antigen specific T cells. We ob- served that the anatomical location deeply influenced the state of CD4+ and CD8+ T lymphocytes. In fact, TIM-3 expression was in- creased by 2 fold on TILs compared to splenic and lymphoid T cells. In the CD8+ compartment, the expression of PD-1 on the surface seemed to be restricted to the tumor micro-environment, while CD4 + T cells had a high expression of PD-1 also in lymphoid organs. Interestingly, we found that the levels of PD-1 were significantly higher on CD8+ T cells than on CD4+ T cells into the tumor micro- environment (p < 0.0001). Conclusions In conclusion, we demonstrated that the efficacy of immune check- point inhibitors might be strongly enhanced by their combination with cancer vaccines. PeptiCRAd was able to increase the number of antigen-specific T cells and PD-L1 blockade prevented their exhaus- tion, resulting in long-lasting immunological memory and increased median survival

Measuring the Optical Point Spread Function of FACT Using the Cherenkov Camera

FACT, the First G-APD Cherenkov Telescope, is an Imaging Air Cherenkov Telescope (IACT) operating since 2011 at the Observatorio del Roque de los Muchachos on the Canary Island of La Palma. As typical for IACTs, its reflector is comprised of smaller mirror facets and not protected by a dome. In the case of FACT, 30 hexagonal facets form a total mirror area of 9.5 m 2 . Hence, it is crucial to monitor the optical properties of this system and realign the facets if necessary. Up to now, measuring the Point Spread Function of FACT required human interaction to mount a screen and an optical camera. In this contribution, a new method to measure the optical Point Spread Function using directly the Cherenkov camera of the telescope is presented. Inspired by the method radio telescopes use to determine their resolution, the telescope is pointed towards a fixed position on the trajectory of a star. During the star’s passage through the field of view, the camera is read out using a fixed rate. In each event, the pedestal variance is determined for each pixel. This value is directly correlated with the amount of night sky background light a pixel received. Translating the time of the measurement to the position of the star in the camera enables to determine the optical point spread function from this measurement. As the measurement is done for each pixel along the trajectory of the star, the Point Spread Function can be determined not only for the camera center but for the entire field of view. In this contribution, the new method will also be compared with the existing methods of determining the optical Point Spread Function: direct measurement with an optical camera and the width of Muon ring eventsISSN:1824-803

SARS-CoV-2 vaccination modelling for safe surgery to save lives: data from an international prospective cohort study

Background Preoperative SARS-CoV-2 vaccination could support safer elective surgery. Vaccine numbers are limited so this study aimed to inform their prioritization by modelling. Methods The primary outcome was the number needed to vaccinate (NNV) to prevent one COVID-19-related death in 1 year. NNVs were based on postoperative SARS-CoV-2 rates and mortality in an international cohort study (surgical patients), and community SARS-CoV-2 incidence and case fatality data (general population). NNV estimates were stratified by age (18-49, 50-69, 70 or more years) and type of surgery. Best- and worst-case scenarios were used to describe uncertainty. Results NNVs were more favourable in surgical patients than the general population. The most favourable NNVs were in patients aged 70 years or more needing cancer surgery (351; best case 196, worst case 816) or non-cancer surgery (733; best case 407, worst case 1664). Both exceeded the NNV in the general population (1840; best case 1196, worst case 3066). NNVs for surgical patients remained favourable at a range of SARS-CoV-2 incidence rates in sensitivity analysis modelling. Globally, prioritizing preoperative vaccination of patients needing elective surgery ahead of the general population could prevent an additional 58 687 (best case 115 007, worst case 20 177) COVID-19-related deaths in 1 year. Conclusion As global roll out of SARS-CoV-2 vaccination proceeds, patients needing elective surgery should be prioritized ahead of the general population.The aim of this study was to inform vaccination prioritization by modelling the impact of vaccination on elective inpatient surgery. The study found that patients aged at least 70 years needing elective surgery should be prioritized alongside other high-risk groups during early vaccination programmes. Once vaccines are rolled out to younger populations, prioritizing surgical patients is advantageous